Skip to Content
MilliporeSigma

Development of novel nanoparticle for bone cancer.

Journal of biomedical nanotechnology (2014-05-09)
Beatriz Ferreira de Carvalho Patricio, Marta de Souza Albernaz, Michelle Alvares Sarcinelli, Samira Marques de Carvalho, Ralph Santos-Oliveira, Gilberto Weissmüller
ABSTRACT

Bone metastasis is responsible for up to 99% of bone tumors. As no cure has yet to be discovered, available treatments simply strive to improve quality of life. One of such treatments is the use of EDTMP (ethylenediamine-tetramethylenephosphonic acid) labeled with Samarium-153, which has been shown to improve survival in 70-80% of patients treated. A major disadvantage of this radiopharmaceutical is its superficial delivery, resulting in the need for multiple doses. The current work describes novel polymeric nanoparticles of EDTMP and evaluation of their biodistribution in vivo. Nanoparticles were prepared using a double emulsion-solvent evaporation method and characterized by AFM (atomic force microscopy). Nanoparticles (200-500 nm) were then labeled with Technetium-99m for biodistribution analysis in healthy Wistar rats. Polymeric nanoparticles of EDTMP were observed to accumulate at bone tissue for long periods of time (150 min), resulting in prolonged release of EDTMP at the target site. This finding suggests that this novel pharmaceutical formulation of EDTMP provides better targeted delivery than free EDTMP and may be a more optimal treatment for management of bone metastasis pain.

MATERIALS
Product Number
Brand
Product Description

Poly(vinyl alcohol), European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Poly(vinyl alcohol), SAJ first grade, degree of polymerization 500
Supelco
Lactic acid, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Poly(vinyl alcohol), Fully hydrolyzed
Sigma-Aldrich
Poly(vinyl alcohol), 87-90% hydrolyzed, average mol wt 30,000-70,000
Sigma-Aldrich
Lactic acid, meets USP testing specifications
Sigma-Aldrich
Mowiol® 10-98, Mw ~61,000
Sigma-Aldrich
Poly(vinyl alcohol), average Mw 13,000-23,000, 98% hydrolyzed
Sigma-Aldrich
Mowiol® 8-88, Mw ~67,000
Sigma-Aldrich
Mowiol® 4-98, Mw ~27,000
Sigma-Aldrich
Poly(vinyl alcohol), Mw 31,000-50,000, 98-99% hydrolyzed
Sigma-Aldrich
Poly(vinyl alcohol), Mw 13,000-23,000, 87-89% hydrolyzed
Sigma-Aldrich
Poly(vinyl alcohol), average Mw 85,000-124,000, 87-89% hydrolyzed
Sigma-Aldrich
Poly(vinyl alcohol), average Mw 146,000-186,000, 87-89% hydrolyzed
Sigma-Aldrich
Poly(vinyl alcohol), Mw 85,000-124,000, 99+% hydrolyzed
Sigma-Aldrich
Lactic acid, natural, ≥85%
Sigma-Aldrich
Lactic acid, 85%, FCC
Sigma-Aldrich
Poly(vinyl alcohol), Mw 89,000-98,000, 99+% hydrolyzed
Sigma-Aldrich
Poly(vinyl alcohol), Mw 9,000-10,000, 80% hydrolyzed
Sigma-Aldrich
Poly(vinyl alcohol), average Mw 31,000-50,000, 87-89% hydrolyzed
Sigma-Aldrich
Poly(vinyl alcohol), Mw 146,000-186,000, 99+% hydrolyzed
Sigma-Aldrich
Poly(vinyl alcohol), average Mw 130,000, 99+% hydrolyzed
Sigma-Aldrich
Mowiol® 20-98, Mw ~125,000
USP
Lactic acid, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Mowiol® 4-88, Mw ~31,000
Sigma-Aldrich
Mowiol® 6-98, Mw ~47,000
Sigma-Aldrich
DL-Lactic acid, JIS special grade, 85.0-92.0%
Sigma-Aldrich
DL-Lactic acid, 85 % (w/w), syrup
Sigma-Aldrich
Kuraray Poval ®56-98, Mw ~195,000
Sigma-Aldrich
Lactic acid solution, ACS reagent, ≥85%